"her2 breast cancer" trang 2 - tải miễn phí từ tailieunhanh
A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease

A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease
7    58    1
A clinicopathological study and survival analysis of 99 breast cancers with HER2/ CEP17 ratio≥2.0 and an average HER2 copy number

A clinicopathological study and survival analysis of 99 breast cancers with HER2/ CEP17 ratio≥2.0 and an average HER2 copy number
13    3    1
A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: A study protocol

A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: A study protocol
5    82    1
SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: A multicenter experience based on 840 cases

SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: A multicenter experience based on 840 cases
11    55    1
Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells

Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells
18    42    1
Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016

Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016
13    35    1
Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas

Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas
13    50    1
Prognostic contribution of mammographic breast density and HER2 overexpression to the Nottingham Prognostic Index in patients with invasive breast cancer

Prognostic contribution of mammographic breast density and HER2 overexpression to the Nottingham Prognostic Index in patients with invasive breast cancer
9    47    1
Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry

Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry
7    39    1
Predictors of breast cancer cell types and their prognostic power in breast cancer patients

Predictors of breast cancer cell types and their prognostic power in breast cancer patients
13    31    1
A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2− early breast cancer in the United States

A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2− early breast cancer in the United States
10    24    1
Pembrolizumab in combination with gemcitabine for patients with HER2‑negative advanced breast cancer: GEICAM/2015–04 (PANGEA‑Breast) study

Pembrolizumab in combination with gemcitabine for patients with HER2‑negative advanced breast cancer: GEICAM/2015–04 (PANGEA‑Breast) study
13    10    1
Characteristics of HER2-positive breast cancer, and the current use of anti HER2 therapy and its related factors

Characteristics of HER2-positive breast cancer, and the current use of anti HER2 therapy and its related factors
8    1    1
Characteristics of HER2-positive breast cancer, and the current use of anti HER2 therapy and its related factors

Characteristics of HER2-positive breast cancer, and the current use of anti HER2 therapy and its related factors
8    1    1
High score of LDH plus dNLR predicts poor survival in patients with HER2- positive advanced breast cancer treated with trastuzumab emtansine

High score of LDH plus dNLR predicts poor survival in patients with HER2- positive advanced breast cancer treated with trastuzumab emtansine
13    36    3
Biodegradable gellan gum hydrogels loaded with paclitaxel for HER2+ breast cancer local therapy

Biodegradable gellan gum hydrogels loaded with paclitaxel for HER2+ breast cancer local therapy
15    12    1
Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value

Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value
18    30    1
Association between ESR1, ESR2, HER2, UGT1A4, and UGT2B7 polymorphisms and breast Cancer in Jordan: A case-control study

Association between ESR1, ESR2, HER2, UGT1A4, and UGT2B7 polymorphisms and breast Cancer in Jordan: A case-control study
10    53    0
Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2- negative metastatic breast cancer: A network meta-analysis

Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2- negative metastatic breast cancer: A network meta-analysis
17    79    0
Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy

Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy
9    90    0